Bristol-Myers Squibb (NYSE:BMY) Shares Sold by DMC Group LLC

DMC Group LLC reduced its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 3.2% in the 2nd quarter, HoldingsChannel reports. The firm owned 10,130 shares of the biopharmaceutical company’s stock after selling 340 shares during the period. DMC Group LLC’s holdings in Bristol-Myers Squibb were worth $648,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Symphony Financial Ltd. Co. increased its stake in Bristol-Myers Squibb by 15.9% in the 2nd quarter. Symphony Financial Ltd. Co. now owns 4,786 shares of the biopharmaceutical company’s stock valued at $306,000 after purchasing an additional 656 shares in the last quarter. Keel Point LLC raised its stake in shares of Bristol-Myers Squibb by 24.5% during the 2nd quarter. Keel Point LLC now owns 4,319 shares of the biopharmaceutical company’s stock worth $276,000 after buying an additional 851 shares during the last quarter. Sage Capital Advisors llc boosted its position in shares of Bristol-Myers Squibb by 14.2% in the 2nd quarter. Sage Capital Advisors llc now owns 67,286 shares of the biopharmaceutical company’s stock worth $4,303,000 after buying an additional 8,377 shares in the last quarter. Lantz Financial LLC grew its stake in Bristol-Myers Squibb by 6.3% in the 2nd quarter. Lantz Financial LLC now owns 5,951 shares of the biopharmaceutical company’s stock valued at $381,000 after acquiring an additional 352 shares during the last quarter. Finally, Sciencast Management LP increased its holdings in Bristol-Myers Squibb by 214.0% during the 2nd quarter. Sciencast Management LP now owns 18,043 shares of the biopharmaceutical company’s stock valued at $1,137,000 after acquiring an additional 12,296 shares in the last quarter. Institutional investors and hedge funds own 74.98% of the company’s stock.

Insiders Place Their Bets

In other Bristol-Myers Squibb news, EVP Ann Powell sold 17,986 shares of the stock in a transaction that occurred on Thursday, August 24th. The shares were sold at an average price of $61.25, for a total value of $1,101,642.50. Following the completion of the sale, the executive vice president now owns 27,868 shares of the company’s stock, valued at $1,706,915. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, EVP Ann Powell sold 17,986 shares of Bristol-Myers Squibb stock in a transaction dated Thursday, August 24th. The stock was sold at an average price of $61.25, for a total transaction of $1,101,642.50. Following the sale, the executive vice president now directly owns 27,868 shares of the company’s stock, valued at $1,706,915. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Robert M. Plenge sold 732 shares of the firm’s stock in a transaction that occurred on Thursday, August 3rd. The shares were sold at an average price of $61.14, for a total value of $44,754.48. Following the sale, the executive vice president now owns 6,584 shares of the company’s stock, valued at approximately $402,545.76. The disclosure for this sale can be found here. 0.08% of the stock is currently owned by insiders.

Bristol-Myers Squibb Trading Down 0.1 %

Shares of NYSE BMY traded down $0.07 during midday trading on Tuesday, hitting $58.51. The stock had a trading volume of 3,662,744 shares, compared to its average volume of 8,971,009. The company has a fifty day moving average price of $61.62 and a 200 day moving average price of $65.11. The company has a market capitalization of $122.23 billion, a price-to-earnings ratio of 15.58, a PEG ratio of 1.57 and a beta of 0.42. Bristol-Myers Squibb has a 1-year low of $58.33 and a 1-year high of $81.43. The company has a quick ratio of 1.28, a current ratio of 1.39 and a debt-to-equity ratio of 1.08.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.99 by ($0.24). Bristol-Myers Squibb had a return on equity of 50.51% and a net margin of 17.62%. The business had revenue of $11.23 billion during the quarter, compared to analyst estimates of $11.81 billion. During the same period in the previous year, the company earned $1.93 EPS. Bristol-Myers Squibb’s revenue was down 5.6% on a year-over-year basis. On average, analysts predict that Bristol-Myers Squibb will post 7.44 earnings per share for the current year.

Analysts Set New Price Targets

BMY has been the topic of several research reports. SVB Securities started coverage on shares of Bristol-Myers Squibb in a research report on Monday, July 10th. They issued a “market perform” rating and a $66.00 price target on the stock. SVB Leerink restated a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, July 10th. BMO Capital Markets dropped their price objective on Bristol-Myers Squibb from $87.00 to $79.00 and set an “outperform” rating for the company in a research report on Friday, July 28th. Atlantic Securities reduced their target price on shares of Bristol-Myers Squibb from $90.00 to $85.00 and set an “overweight” rating on the stock in a report on Friday, July 28th. Finally, HSBC began coverage on shares of Bristol-Myers Squibb in a report on Friday, July 14th. They set a “reduce” rating and a $56.00 price target for the company. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $70.67.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.